Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 14 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Mutation Medicine & Life Sciences
Genes Medicine & Life Sciences
Leukemia, Myeloid, Chronic Phase Medicine & Life Sciences
Leukemia Medicine & Life Sciences
Genome Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2008 2022

Research Output 1998 2017

  • 1038 Citations
  • 15 Scopus h-Index
  • 22 Article
  • 7 Review article
  • 2 Letter

Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia

Ganti, B. R., Marini, B. L., Nagel, J., Bixby, D. & Perissinotti, A. J. Feb 1 2017 In : Supportive Care in Cancer. 25, 2, p. 541-547 7 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Recurrence
Drug Therapy
Levofloxacin
Bacteremia
1 Citations

Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma

Koschmann, C., Zamler, D., MacKay, A., Robinson, D., Wu, Y. M., Doherty, R., Marini, B., Tran, D., Garton, H., Muraszko, K., Robertson, P., Leonard, M., Zhao, L., Bixby, D., Peterson, L., Camelo-Piragua, S., Jones, C., Mody, R., Lowenstein, P. R. & Castro, M. G. 2016 In : Oncotarget. 7, 40, p. 65696-65706 11 p.

Research output: Contribution to journalArticle

Glioma
Pediatrics
Mutation
Datasets
Primary Cell Culture
1 Citations

Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase

Akard, L. P. & Bixby, D. May 3 2016 In : Leukemia and Lymphoma. 57, 5, p. 1002-1014 13 p.

Research output: Contribution to journalReview article

Leukemia, Myeloid, Chronic Phase
Protein-Tyrosine Kinases
Patient Selection
Cost-Benefit Analysis
Neoplasms
3 Citations

FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML

Song, Y. , Magenau, J. , Li, Y. , Braun, T. , Chang, L. , Bixby, D. , Hanauer, D. A. , Chughtai, K. A. , Gatza, E. , Couriel, D. , Goldstein, S. , Pawarode, A. , Reddy, P. , Riwes, M. , Connelly, J. , Harris, A. , Kitko, C. , Levine, J. , Yanik, G. , Parkin, B. & 1 others Choi, S. W. Apr 1 2016 In : Bone Marrow Transplantation. 51, 4, p. 511-520 10 p.

Research output: Contribution to journalArticle

Homologous Transplantation
Protein-Tyrosine Kinases
Cell Transplantation
Recurrence
Cohort Studies
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Single Nucleotide Polymorphism
Genome
B-Lymphocytes
Fluorescence In Situ Hybridization